

Page 5, paragraph 2, before "5'<GT GAT TAA TAA AGC TTC TAA TTC<3'"
insert --(SEQ. ID NO: 5)--.

In the Claims:

1. (Amended) A novel molecule useful for anthrax toxin inhibition in vivo comprising a recombinant protein designated as PA-1, which is a dominant negative inhibitor of PA, wherein the 2 β 2-2 β 3 loop comprises amino acid residues of the amphipathic loop of the homologous toxin iota-comprising:

'iota b toxin' sequence inserted a 2 β 2-2 β 3 loop in the recombinant PA-1:
(SEQ. ID NO: 2) ³⁰²V G V S I S A G Y Q N G F T G N I T T S A G F³²⁴

2. (Amended) The mutated gene encoding the recombinant protein with sequence of base pairs at 2 β 2-2 β 3 loop comprising:

(SEQ. ID NO: 3) GTA GGA GTT TCA ATT TCA GCA GGG TAT CAG AAC GGC
TTT ACT GGT AAT ATC ACT ACA TCT GCA GGA TTT

3. (Amended) The oligonucleotide primers encompassing the mutation:

Primer 1:

(SEQ. ID NO: 4) 5'< ATT ACT AAA TCC TGC AGA TGT AGT GAT ATT ACC AGT
AAA GCC GTT CTG ATA CCC TGC TGA AAT TGA AAC TCC TAC AGT ATT
AGC ATC CCT ACT TGT AGA AGT ATT TTT AC<3'

Primer 2:

(SEQ. ID NO: 5) 5'<GT GAT TAA TAA AGC TTC TAA TTC<3'

4. (Amended) A method for developing the novel recombinant anthrax toxin inhibitor protein as claimed in claim 1, said method comprising steps of:

a. designing the oligonucleotide primers encompassing the mutation site comprising:

Primer 1:

(SEQ. ID NO: 4) 5'< ATT ACT AAA TCC TGC AGA TGT AGT GAT ATT ACC AGT
AAA GCC GTT CTG ATA CCC TGC TGA AAT TGA AAC TCC TAC AGT ATT
AGC ATC CCT ACT TGT AGA AGT ATT TTT AC<3'